Strategy
Stages
Series ASeries BGrowth
Sectors
HealthcareBiotech
Geographies
USABoston, MA
Check size
$5M-$100MPortfolio
2 totalCo-Investors
9Latest Pulse
- Aug 27, 2026AusperBio Raises $120M for Hepatitis B CureAusperBio Therapeutics raised a $120 million Series C led by a strategic investor with RA Capital joining, bringing total funding to $360 million as its lead hepatitis B therapy enters Phase 3.→
- Jul 2, 2026Celea Therapeutics Raises $180M Series B for Pulmonary Fibrosis DrugCelea Therapeutics, a clinical-stage biotech spun out of PureTech developing deupirfenidone for idiopathic pulmonary fibrosis, announced a $180 million Series B on July 2, led by RA Capital and Leaps by Bayer, with PureTech and additional unnamed.→